Hwang J, Choi S, Kim B, Son S, Yoon J, Kim K
J Nanobiotechnology. 2025; 23(1):44.
PMID: 39856746
PMC: 11761773.
DOI: 10.1186/s12951-025-03100-y.
Rodriguez L, Lee H, Li J, Martin R, Han D, Xu S
Antimicrob Agents Chemother. 2024; 69(2):e0123824.
PMID: 39699245
PMC: 11823660.
DOI: 10.1128/aac.01238-24.
Jubair M, Hossain M, Begum M, Moon S, Islam S, Karim M
Influenza Other Respir Viruses. 2024; 18(10):e70019.
PMID: 39440811
PMC: 11497173.
DOI: 10.1111/irv.70019.
Schoefbaenker M, Gunther T, Lorentzen E, Romberg M, Hennies M, Neddermeyer R
PLoS Pathog. 2024; 20(10):e1012624.
PMID: 39405332
PMC: 11508484.
DOI: 10.1371/journal.ppat.1012624.
Nooruzzaman M, Johnson K, Rani R, Finkelsztein E, Caserta L, Kodiyanplakkal R
Nat Commun. 2024; 15(1):7999.
PMID: 39294134
PMC: 11411086.
DOI: 10.1038/s41467-024-51924-3.
Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China.
Liu Y, Guo Y, Zhan H, Liu X, Li X, Cui J
BMC Infect Dis. 2024; 24(1):809.
PMID: 39123106
PMC: 11316362.
DOI: 10.1186/s12879-024-09652-y.
Amidino-rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors of SARS-CoV-2 replication through inhibition of viral protein synthesis.
Keiser P, Zhang W, Ricca M, Wacquiez A, Grimins A, Cencic R
Antiviral Res. 2024; 230:105976.
PMID: 39117283
PMC: 11434215.
DOI: 10.1016/j.antiviral.2024.105976.
Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials.
da Silva Amorim A, Sobalvarro J, Torres L, Dos Reis T
Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9573-9589.
PMID: 39031183
DOI: 10.1007/s00210-024-03298-y.
Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.
Nooruzzaman M, Johnson K, Rani R, Finkelsztein E, Caserta L, Kodiyanplakkal R
medRxiv. 2024; .
PMID: 38946967
PMC: 11213110.
DOI: 10.1101/2024.06.14.24308523.
Real-world severe COVID-19 outcomes associated with use of antivirals and neutralising monoclonal antibodies in Scotland.
Tibble H, Mueller T, Proud E, Hall E, Kurdi A, Robertson C
NPJ Prim Care Respir Med. 2024; 34(1):17.
PMID: 38942748
PMC: 11213868.
DOI: 10.1038/s41533-024-00374-x.
Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review).
Zhang T, Yang D, Tang L, Hu Y
Mol Med Rep. 2024; 30(2).
PMID: 38940338
PMC: 11228696.
DOI: 10.3892/mmr.2024.13272.
Genetic barrier to resistance: a critical parameter for efficacy of neutralizing monoclonal antibodies against SARS-CoV-2 in a nonhuman primate model.
Stahl-Hennig C, Peter A, Cordsmeier A, Stolte-Leeb N, Vestweber R, Socher E
J Virol. 2024; 98(7):e0062824.
PMID: 38899895
PMC: 11265388.
DOI: 10.1128/jvi.00628-24.
A Robust Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T- and B-Cell Response Is Associated With Early Viral Clearance in SARS-CoV-2 Omicron-Infected Immunocompromised Individuals.
Vergouwe M, Biemond J, van der Straten K, van Pul L, Kerster G, Claireaux M
J Infect Dis. 2024; 230(4):e860-e871.
PMID: 38843052
PMC: 11481360.
DOI: 10.1093/infdis/jiae306.
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs.
Iketani S, Ho D
Cell Chem Biol. 2024; 31(4):632-657.
PMID: 38640902
PMC: 11084874.
DOI: 10.1016/j.chembiol.2024.03.008.
Prophylactic efficacy of an intranasal spray with 2 synergetic antibodies neutralizing Omicron.
Zhang X, Luo F, Zhang H, Guo H, Zhou J, Li T
JCI Insight. 2024; 9(7).
PMID: 38587080
PMC: 11128199.
DOI: 10.1172/jci.insight.171034.
Immune System Deficiencies Do Not Alter SARS-CoV-2 Evolutionary Rate but Favour the Emergence of Mutations by Extending Viral Persistence.
Manuto L, Bado M, Cola M, Vanzo E, Antonello M, Mazzotti G
Viruses. 2024; 16(3).
PMID: 38543811
PMC: 10974344.
DOI: 10.3390/v16030447.
Sensitive detection of SARS-CoV-2 main protease 3CL with an engineered ribonuclease zymogen.
Wralstad E, Raines R
Protein Sci. 2024; 33(4):e4916.
PMID: 38501598
PMC: 10949392.
DOI: 10.1002/pro.4916.
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.
Huygens S, GeurtsvanKessel C, Gharbharan A, Bogers S, Worp N, Boter M
Clin Infect Dis. 2024; 78(6):1514-1521.
PMID: 38445721
PMC: 11175671.
DOI: 10.1093/cid/ciae026.
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.
Arevalo-Romero J, Chingate-Lopez S, Camacho B, Almeciga-Diaz C, Ramirez-Segura C
Heliyon. 2024; 10(5):e26423.
PMID: 38434363
PMC: 10907543.
DOI: 10.1016/j.heliyon.2024.e26423.
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants.
Focosi D, Casadevall A, Franchini M, Maggi F
Viruses. 2024; 16(2).
PMID: 38399991
PMC: 10891757.
DOI: 10.3390/v16020217.
